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Europe
 July 5th 2018, 
 EMA reviewing medicines containing valsartan from 
Zhejiang Huahai following detection of an impurity 
(NDMA). 
 MHRA UK :recalling all batches of valsartan containing 
medicines made by Actavis Group PTC (now Accord) 
and Dexcel Pharma Ltd due to contamination. 
 July  17th 2018,
 EMA  gathering details of the company’s manufacturing 
processes, following changes introduced in 2012 that are 
believed to have produced NDMA as a side product. 
 2 Agt 18, 
 EMA is doing preliminary assessment of possible risks to 
patients.
 Estimation: one extra case of cancer for every 5,000 patients 
taking the affected medicines at the highest valsartan dose 
(320 mg) every day for 7 years [(based on average levels of this 
impurity detected in the active substance from Zhejiang 
Huahai Pharmaceuticals (60 parts per million)].
 Extrapolated from animal studies and should be considered in 
the context of the lifetime risk of cancer in the EU and NDMA 
exposure from other sources. 
 Assumption: NDMA present in the active substance is carried 
over in the final product in the same amount. 
 10 Agt 2018
 low levels of N-nitrosodimethylamine (NDMA) have been 
detected in the valsartan active substance manufactured by a 
second company, Zhejiang Tianyu. 
 The NDMA levels detected in batches of valsartan from 
Zhejiang Tianyu is much lower than levels seen in the active 
substance from Zhejiang Huahai
 20 Agt 2018
 The suspension of the certificate by the European Directorate 
for the Quality of Medicines and Healthcare. 
 Zhejiang Huahai and Zhejiang Tianyu are no longer authorize 
to supply valsartan active substance in EU.
US (FDA)
 July 13th 2018 
 FDA announced a recall of certain batches of valsartan tablets 
because of an impurity, a chemical known as N-
nitrosodimethylamine (NDMA).
 July 18 2018
 Updating list of valsartan-containing products that are being 
recalled
 The presence of NDMA is related to changes in the way the 
active substance was manufactured. Some levels of the 
impurity may have been in the valsartan-containing products 
for as long as four years.
 July 24, 2018
 FDA publish list of valsartan -containing products not 
included in the recall
 July 27, 2018
 FDA updating list of valsartan –containing products that 
are being recalled  (adding lists from repackaging 
companies)
 FDA analysis of NDMA levels in recalled valsartan in the 
US.
 US EPA: consuming up to 96ng NDMA/day is considered safe 
– with this amount during a person’s life time would result in 
less than one additional case of cancer for every 100,000 
people (<1:100.000).
 Some levels of the impurity may have been in the valsartan-
containing products for as long as four years. 
 The estimation that if 8,000 people took the highest valsartan
dose (320 mg) from the recalled batches daily for the full four 
years, there may be one additional case of cancer over the 
lifetimes of these 8,000 people (1:8000)
 August 2, 2018
 Updating list of products included in the recall and not 
included in the recall
 Reminding API manufacturers to evaluate process of 
API manufacturing for unsafe  impurities.
 August 9, 2018
 Updating list of products included in the recall and not 
included in the recall
 Recall of valsartan-containing products manufactured 
by Hetero Labs limited in India (using similar process 
similar to Zhejiang Huahai Pharmaceuticals, although 
the level is lower)
 August 20, 2018
 Updating list of products included in the recall and not 
included in the recall.
 Providing information on NDMA levels in some foods
 August 22, 2018
 Updating list of products included in the recall and not 
included in the recall.
 Release analytical method to detect NDMA (GC/MS 
headspace method) in valsartan API and finished 
products,
Indonesia (BPOM)
 July 12, 2018
 Announce valsartan recall following EMA 
announcement
 List of valsartan-containing product-API from Zhejiang 
Huahai:
 Varten tablet 80mg, 160 mg (PT Actavis Indonesia)
 Valesco kaplet salut selaput 40mg, 80mg, 160mg (PT Dipa
Pharmalab Intersains)
Indonesia (BPOM)
 List of valsartan-containing products -API not from 
Zhejiang Huahai:
 Valsartan, Valdix (Dexa Medica)
 Valsartan (Etercon)
 Valsif (Ferron), Diovan
 Co-Diovan, Exforge, Uperio (Novartis)
 Tyoval (Novell)
N-nitrosodimethylamine
(NDMA)
N-nitrosodimethylamine (NDMA) 
who
 N-Nitrosodimethylamine (NDMA) is the simplest 
dialkylnitrosamine. 
 Volatile, combustible, yellow, oily liquid. 
 Susceptible to photolytic breakdown due to its 
absorption of ultraviolet light
 Sources:
 major releases of NDMA have been from the 
manufacture of pesticides, rubber tires, and dyes. 
 may also form under natural conditions in air, water, and 
soil as a result of chemical, photochemical, biological 
processes .
 Also detected in drinking-water and in automobile 
exhaust. 
 Human exposure
 Occupational: rubber, tannery, fish processing, dye, and 
surfactant industries.
 Food ingestion (e.g., cured meat products,smoked fish, 
cheeses, pickled and salt-preserved foods, low-fat dried 
milk products).
 drinking contaminated water
 breathing cigarette smoke and contaminated ambient 
air
 etc
 Acute Effects:
 Liver damage in humans, with symptoms that include 
nausea, vomiting, headaches, and malaise. 
 Hematological and severe liver effects (hemorrhagic 
necrosis) were reported in animals acutely exposed via 
inhalation and ingestion. 
 Chronic Effects (Non-cancer):
 Chronic exposure of humans to N-
nitrosodimethylamine may cause liver damage (jaundice 
and swelling)and low platelet counts.
 Chronic oral exposure has resulted in severe liver 
damage in animals. 
 Reproductive/Developmental Effects:
 No information is available on the reproductive or 
developmental effects of NDMA in humans.
 Increased fetal mortality was observed but no birth 
defects were noted in rats.
 Has been shown to cause cancer in the offspring of rats, 
mice, and hamsters. 
 Cancer Risk:
 Limited data from human studies because human 
exposure to nitrosamines generally results from contact 
with mixtures of these compounds.
 Carcinogenic in a number of animal species, inducing 
tumors in various organs and by various routes of 
exposure.
 Increased incidences of liver, kidney, and lung tumors in 
rats and mice.
Song P, Wu L and Guan W. Dietary Nitrates, 
Nitrites, and Nitrosamines Intake and the 
Risk of Gastric Cancer: A Meta-Analysis. 
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 Description of studies
 11 studies on NDMA (7 cohort, 4 case-control)
 Mostly  conducted in Europe  (Italy, France, 
Netherlands,  Sweden, Finnish, European), and 
Uruguay.
 Dietary NDMA intake and risk of cancer
 RR for high vs low intake was 1.34 (95%CI 1.02-1.76) with 
obvious evidence of heterogeneity (I2=75.8%, p<0.001)

•Dose response analysis
 7 studies were included
 Non linear trend toward gastric cancer risk with 
increasing NDMA intake following an increase in the 
risk of NDMA intake up to 0.12 mcg/day.
 Conclusion of the article:
 Increase consumption of NDMA, increase risk of gastric 
cancer
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